Part 2. Applying mechanistic research to risk assessmentUse of quantitative modelling in methylene chloride risk assessment
References (58)
- et al.
Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
Toxicol. Appl. Pharmacol.
(1987) - et al.
Negative selection in hepatic tumor promotion in relation to cancer risk assessment
Toxicology
(1995) Time concepts in physics, biology and pharmacokinetics
J. Pharmacol. Sci.
(1986)- et al.
Dichloromethane (methylene chloride): Metabolism to formaldehyde and formation of DNA-protein cross-links in B6C3F1 mice and Syrian golden hamsters
Toxicol. Appl. Pharmacol.
(1992) Cell proliferation in the bladder and implications for cancers risk assessment
Toxicology
(1995)Cancer and non-cancer risk assessment: Not so different if you consider mechanisms
Toxicology
(1995)- et al.
Biological basis for extrapolation across mammalian species
Regul. Toxicol. Pharmacol.
(1986) - et al.
Dioxins: Model chemicals for receptor-mediated toxicity
Toxicology
(1995) - et al.
Comparison of experimental and theoretical parameters of the Moolgavkar-Venzon-Knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis
Toxicology
(1995) Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids
Toxicology
(1995)
Biochemical mechanisms and cancer risk assessment models for dioxin
Toxicology
(1995)
Hepatic and pulmonary carcinogenicity of methylene chloride in mice: A search for mechanisms
Toxicology
(1995)
Incorporating cell proliferation kinetics into models for cancer risk assessment
Toxicology
(1995)
Man versus beast: Pharmacokinetic scaling in mammals
J. Pharmacol. Sci.
(1986)
Biological modeling of 5-fluorouracil developmental toxicity
Toxicology
(1995)
Interspecies extrapolation of pharmacokinetics
J. Theor. Biol.
(1990)
Extrapolation of animal toxicity data to man
Regul. Toxicol. Pharmacol.
(1988)
Quantitative relations in the physiological constitution of mammals
Science
(1949)
Interspecies scaling, allometry physiological time and the ground plan of pharmacokinetics
J. Pharmacol. Biopharm.
(1982)
Evolutionary biology, animal behavior fourth-dimensional space and the raison d'être of drug metabolism and pharmacokinetics
Drug Metab. Rev.
(1983)
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm
Drug Metab. Rev.
(1984)
Principles of Animal Extrapolation
(1983)
Extrapolation from animal data
In vitro metabolism and covalent binding of dichloromethane (DCM) in hepatocytes isolated from mice and hamsters
The Toxicologist
(1994)
Interspecies comparison for carcinogenic potency to humans
Animal scale-up
J. Pharmacol. Biopharm.
(1973)
Interspecies correlation of plasma concentration history of methotrexate (NSC-740)
Cancer Chemother. Rep. Part 1
(1970)
Addendum to the health assessment document for dichloromethane (methylene chloride): Updated carcinogenicity assessment of dichloromethane (methylene chloride)
Guidelines for carcinogen risk assessment
Fed. Reg.
(1986)
Cited by (7)
Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations
2006, Regulatory Toxicology and PharmacologyNonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice
2011, Drug Metabolism and DispositionMethods for identifying a default cross-species scaling factor
2006, Human and Ecological Risk AssessmentActivation of dihaloalkanes by thiol-dependent mechanisms
2003, Journal of Biochemistry and Molecular BiologyDose-Response analyses of the carcinogenic effects of trichloroethylene in experimental animals
2000, Environmental Health Perspectives
- ∗
Present address: Harvard Center for Risk Analysis, 718 Huntington Ave., Boston, MA 02115, USA.
Copyright © 1995 Published by Elsevier Ireland Ltd.